CBA
ALLO icon

Coastal Bridge Advisors’s Allogene Therapeutics ALLO Stock Holding History

Coastal Bridge Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.3K Hold
21,789
– – ﹤0.01% 465
2026
Q1 		$53.2K Hold
21,789
– – ﹤0.01% 444
2025
Q4 		$29.9K Hold
21,789
– – ﹤0.01% 457
2025
Q3 		$27K Sell
21,789
-199,270
-90% -$238K ﹤0.01% 458
2025
Q2 		$250K Hold
221,059
– – 0.02% 384
2025
Q1 		$323K Hold
221,059
– – 0.03% 331
2024
Q4 		$471K Sell
221,059
-184,788
-46% -$456K 0.12% 99
2024
Q3 		$1.14M Sell
405,847
-1,000
-0.2% -$2.67K 0.28% 60
2024
Q2 		$948K Hold
406,847
– – 0.24% 64
2024
Q1 		$1.82M Hold
406,847
– – 0.42% 43
2023
Q4 		$1.31M Hold
406,847
– – 0.33% 52
2023
Q3 		$1.29M Hold
406,847
– – 0.35% 48
2023
Q2 		$2.02M Hold
406,847
– – 0.5% 37
2023
Q1 		$2.01M Hold
406,847
– – 0.51% 37
2022
Q4 		$2.56M Buy
406,847
+7,418
+2% +$68.7K 0.73% 29
2022
Q3 		$4.31M Sell
399,429
-2,500
-0.6% -$34K 1.16% 19
2022
Q2 		$4.58M Hold
401,929
– – 1.41% 14
2022
Q1 		$3.66M Buy
401,929
+100,000
+33% +$1.04M 0.84% 27
2021
Q4 		$4.5M Buy
301,929
+689
+0.2% +$12.2K 0.94% 25
2021
Q3 		$7.74M Sell
301,240
-2,000
-0.7% -$47.5K 1.79% 12
2021
Q2 		$7.91M Hold
303,240
– – 1.62% 12
2021
Q1 		$10.7M Sell
303,240
-82,584
-21% -$2.79M 1.96% 9
2020
Q4 		$9.74M Sell
385,824
-63,272
-14% -$2.06M 1.93% 8
2020
Q3 		$16.9M Sell
449,096
-14,021
-3% -$529K 5.16% 5
2020
Q2 		$19.8M Sell
463,117
-207,305
-31% -$7.5M 6.33% 3
2020
Q1 		$13M Sell
670,422
-8,417
-1% -$200K 4.78% 5
2019
Q4 		$17.6M Sell
678,839
-145,778
-18% -$4.01M 4.58% 6
2019
Q3 		$22.5M Sell
824,617
-331,100
-29% -$9.43M 7.68% 3
2019
Q2 		$31M Buy
1,155,717
+1,002,199
+653% +$27.9M 9.18% 3
2019
Q1 		$4.44M Sell
153,518
-27,482
-15% -$797K 1.55% 8
2018
Q4 		$4.87M Buy
+181,000
New +$4.81M 1.92% 8

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Coastal Bridge Advisors's ALLO Position: Q2 2026 in Review

Coastal Bridge Advisors held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 21,789 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

Coastal Bridge Advisors first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $31M in Q2 2019. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Coastal Bridge Advisors held 21,789 shares of Allogene Therapeutics worth $45.3K as of Q2 2026.
  • Coastal Bridge Advisors left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Coastal Bridge Advisors's portfolio in Q2 2026, its #465 holding.
  • Coastal Bridge Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Coastal Bridge Advisors's Allogene Therapeutics position peaked at $31M in Q2 2019.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Coastal Bridge Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.